brigatinib
Pfizer's Lorbrena Produces Longest Progression-Free Survival Seen in ALK-Positive NSCLC Patients
At five years, 60 percent of patients receiving first-line Lorbrena were alive without progression, according to Phase III data reported at ASCO.
Takeda, Point32Health Deal Could Offer Roadmap for Risk-Sharing Reimbursement in Precision Oncology
Premium
The drugmaker and insurer's outcomes-based agreement offers rebates for ALK-positive NSCLC patients who discontinue Alunbrig after three months.
FDA Approves FoundationOne CDx for Takeda's ALK-Inhibitor
The agency approved Foundation Medicine's tissue-based, next-generation sequencing test to identify patients with ALK-positive NSCLC eligible for Alunbrig.
UK's NICE Recommends Takeda's Alunbrig for ALK Inhibitor-Naïve Advanced NSCLC
The agency recommended the drug based on the results from the Phase III ALTA-1L trial, and after Takeda agreed to offer the drug to NHS England at a discount.
Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies
The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.